In the human body, eight transglutaminases fulfill a broad variety of physiological functions. On the other hand, transglutaminases are involved in the pathophysiology of various disorders. Celiac disease, thrombosis, fibrosis or even cancer and such neurodegenerative diseases as Alzheimer’s, Huntington’s and Parkinson’s disease are just some examples.
Celiac Disease
Zedira’s drug candidate ZED1227 targeting dysregulated TG2 in celiac disease is currently tested in phase 2 clinical trials (proof-of-concept).
read more
Zedira’s drug candidate ZED1227 targeting dysregulated TG2 in celiac disease is currently tested in phase 2 clinical trials (proof-of-concept).
read more
Partnering in Drug Development
Zedira offers its proprietary drug discovery platform for partnering in drug development
read more
Zedira offers its proprietary drug discovery platform for partnering in drug development
read more
Gluten Sensitive Neurological Disorders
Auto-antibodies specific for neuronal transglutaminase (TG6) can be measured with our proprietary ELISA-kits.
New: Analytical service for measurement of TG6-autoantibodies in human serum samples..
read more
Auto-antibodies specific for neuronal transglutaminase (TG6) can be measured with our proprietary ELISA-kits.
New: Analytical service for measurement of TG6-autoantibodies in human serum samples..
read more
Thrombosis / Anticoagulation
Proof-of-principle for safe anticoagulation, meaning anticoagulation without increased bleeding risk using blood coagulation factor FXIIIa-blockers has recently been shown.
read more
Proof-of-principle for safe anticoagulation, meaning anticoagulation without increased bleeding risk using blood coagulation factor FXIIIa-blockers has recently been shown.
read more
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Press release: Zedira announces ISO 9001:2015 certification
Zedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
Artikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
Preview: Catalogue Editorial 2019
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering
Tridegin as FXIIIa inhibitor
Microbial transglutaminase: from discovery to market
Tissue transglutaminase inhibitors
Tissue transglutaminase in Alzheimer’s Disease
Factor XIIIa: novel target for anticoagulation?
Microbial transglutaminase for site-specific protein conjugation
Transglutaminase antibodies in ataxia